Literature DB >> 18190944

Characterization of wild-type and mutant vaccinia virus M2L proteins' abilities to localize to the endoplasmic reticulum and to inhibit NF-kappaB activation during infection.

Olivia Hinthong1, Xiao-Lu Jin, Joanna L Shisler.   

Abstract

Proinflammatory molecules are important for attracting immune effector cells to localized areas of viral infection. One such cellular mechanism facilitating this response is the NF-kappaB transcription factor. While wild-type vaccinia virus expresses multiple products to inhibit NF-kappaB during infection, the attenuated deletion mutant MVA lacks this ability. However, introduction of the wild-type M2L ORF into the MVA genome will re-establish the parental phenotype. As the M2L protein is unique to poxviruses, we characterized it to elucidate its mechanism to quell an inflammatory response. It was discovered that the M2L protein possesses motifs characteristic of ER-localized proteins: an N-terminal signal peptide sequence, C-terminal endoplasmic reticulum (ER) retention and retrieval sequences, and N-linked glycosylation sites. Indeed, the M2L protein was demonstrated to be N-linked glycosylated and expressed early during infection. Furthermore, confocal microscopic analysis revealed that the M2L protein co-localized with cellular ER proteins. Organelle location also affects M2L protein function: the elimination of the N-terminal leader sequence from the M2L protein compromised both its ER location and its ability to inhibit virus-induced NF-kappaB activation. There is only partial ER localization when a second mutant M2L protein lacking potential endoplasmic reticulum retention signal is expressed. However, this C-terminal deleted mutant protein is compromised in its ability to inhibit NF-kappaB activation. Determination of the ER location of the M2L proteins provides important insights for its function in future investigations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18190944      PMCID: PMC2679263          DOI: 10.1016/j.virol.2007.11.034

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  55 in total

1.  IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation.

Authors:  F Mercurio; H Zhu; B W Murray; A Shevchenko; B L Bennett; J Li; D B Young; M Barbosa; M Mann; A Manning; A Rao
Journal:  Science       Date:  1997-10-31       Impact factor: 47.728

2.  A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB.

Authors:  J A DiDonato; M Hayakawa; D M Rothwarf; E Zandi; M Karin
Journal:  Nature       Date:  1997-08-07       Impact factor: 49.962

3.  Activation of NF-kappa B by ER stress requires both Ca2+ and reactive oxygen intermediates as messengers.

Authors:  H L Pahl; P A Baeuerle
Journal:  FEBS Lett       Date:  1996-08-26       Impact factor: 4.124

4.  Expression of influenza virus hemagglutinin activates transcription factor NF-kappa B.

Authors:  H L Pahl; P A Baeuerle
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

5.  The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B.

Authors:  V J Palombella; O J Rando; A L Goldberg; T Maniatis
Journal:  Cell       Date:  1994-09-09       Impact factor: 41.582

6.  Multifocal defects in immune responses in RelB-deficient mice.

Authors:  F Weih; G Warr; H Yang; R Bravo
Journal:  J Immunol       Date:  1997-06-01       Impact factor: 5.422

7.  Host range selection of vaccinia recombinants containing insertions of foreign genes into non-coding sequences.

Authors:  K A Smith; V Stallard; J M Roos; C Hart; N Cormier; L K Cohen; B E Roberts; L G Payne
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

8.  Retrieval of transmembrane proteins to the endoplasmic reticulum.

Authors:  M R Jackson; T Nilsson; P A Peterson
Journal:  J Cell Biol       Date:  1993-04       Impact factor: 10.539

9.  A novel signal transduction pathway from the endoplasmic reticulum to the nucleus is mediated by transcription factor NF-kappa B.

Authors:  H L Pahl; P A Baeuerle
Journal:  EMBO J       Date:  1995-06-01       Impact factor: 11.598

10.  Activation of transcription factor NF-kappaB by the adenovirus E3/19K protein requires its ER retention.

Authors:  H L Pahl; M Sester; H G Burgert; P A Baeuerle
Journal:  J Cell Biol       Date:  1996-02       Impact factor: 10.539

View more
  9 in total

Review 1.  Inhibiting NF-κB activation by small molecules as a therapeutic strategy.

Authors:  Subash C Gupta; Chitra Sundaram; Simone Reuter; Bharat B Aggarwal
Journal:  Biochim Biophys Acta       Date:  2010-05-21

2.  The C11R gene, which encodes the vaccinia virus growth factor, is partially responsible for MVA-induced NF-κB and ERK2 activation.

Authors:  Stefani Martin; Daniel T Harris; Joanna Shisler
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

3.  Genetic Variability of Myxoma Virus Genomes.

Authors:  Christoph Braun; Andrea Thürmer; Rolf Daniel; Anne-Kathrin Schultz; Ingo Bulla; Horst Schirrmeier; Dietmar Mayer; Andreas Neubert; Claus-Peter Czerny
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

4.  Orthopoxviruses require a functional ubiquitin-proteasome system for productive replication.

Authors:  Alastair Teale; Stephanie Campbell; Nick Van Buuren; Wendy C Magee; Kelly Watmough; Brianne Couturier; Robyn Shipclark; Michele Barry
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

5.  Identification of Poxvirus Genome Uncoating and DNA Replication Factors with Mutually Redundant Roles.

Authors:  Baoming Liu; Debasis Panda; Jorge D Mendez-Rios; Sundar Ganesan; Linda S Wyatt; Bernard Moss
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

6.  EVM005: an ectromelia-encoded protein with dual roles in NF-κB inhibition and virulence.

Authors:  Nicholas van Buuren; Kristin Burles; Jill Schriewer; Ninad Mehta; Scott Parker; R Mark Buller; Michele Barry
Journal:  PLoS Pathog       Date:  2014-08-14       Impact factor: 6.823

7.  By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.

Authors:  Patricia Kleinpeter; Christelle Remy-Ziller; Eline Winter; Murielle Gantzer; Virginie Nourtier; Juliette Kempf; Julie Hortelano; Doris Schmitt; Huguette Schultz; Michel Geist; Catherine Brua; Chantal Hoffmann; Yasmin Schlesinger; Dominique Villeval; Christine Thioudellet; Philippe Erbs; Johann Foloppe; Nathalie Silvestre; Laetitia Fend; Eric Quemeneur; Jean-Baptiste Marchand
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

Review 8.  Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.

Authors:  A Volz; G Sutter
Journal:  Adv Virus Res       Date:  2016-08-01       Impact factor: 9.937

9.  Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome.

Authors:  Julie Delaloye; Thierry Roger; Quynh-Giao Steiner-Tardivel; Didier Le Roy; Marlies Knaup Reymond; Shizuo Akira; Virginie Petrilli; Carmen E Gomez; Beatriz Perdiguero; Jürg Tschopp; Giuseppe Pantaleo; Mariano Esteban; Thierry Calandra
Journal:  PLoS Pathog       Date:  2009-06-19       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.